Establishing the World’s Leading Metabolome Analysis Technology and Innovative Diagnostic Methods
First written in FY2017. 5 of 8 entries say "Reframed", first in FY2020. Latest entry: FY2026.
Human Metabolome Technologies moved to the "Worse" side of this theme in 2020.
0 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「The Group's corporate philosophy is to “contribute to people's healthy and fulfilling lives through research and development that uses cutting-edge metabolome analysis technology and biotechnology for the children of the future.” Its vision is to “provide added value to customers and users as a bioanalysis platform provider that supports everything from research and development to production efficiency, quality assurance and testing by making full use of proprietary mass spectrometry technology.”」
The vision changed from the previous description as a healthcare solution provider to a “bioanalysis platform provider” supporting everything from research and development to production efficiency, quality assurance and testing. - FY2024RestatedAnnual report
「The Group's corporate philosophy is to “contribute to people's healthy and fulfilling lives through research and development that uses cutting-edge metabolome analysis technology and biotechnology for the children of the future.” To achieve this, it is working to become a “healthcare solution provider” that contributes to the creation of groundbreaking healthcare products and services as the best partner for people engaged in research and development in the healthcare field.」
The Group continues to pursue its corporate philosophy of becoming a healthcare solution provider based on cutting-edge metabolome analysis technology and biotechnology. - FY2021ReframedAnnual report
「The Group's corporate philosophy is to “contribute to people's healthy and fulfilling lives through research and development that uses cutting-edge metabolome analysis technology and biotechnology for the children of the future.” To achieve this, it is working to become a “healthcare solution provider” that contributes to the creation of groundbreaking healthcare products and services as the best partner for people engaged in research and development in the healthcare field.」
In addition to its previous vision of “world-leading metabolome analysis technology and innovative testing methods,” the Group is emphasizing its corporate identity as a healthcare solution provider that creates healthcare products and services. - FY2020ReframedAnnual report
「The Group's vision is to become a biotechnology venture that establishes the world's leading metabolome analysis technology and the definitive approach to biomarker discovery, and creates innovative testing methods.」
The wording changed from the previous “innovative diagnostic methods” to “innovative testing methods,” but the core vision of creating new testing methods based on world-leading analysis technology and biomarker discovery has been maintained. - FY2019RestatedAnnual report
「The Group's vision is to become a biotechnology venture that establishes the world's leading metabolome analysis technology and the definitive approach to biomarker discovery, and creates innovative diagnostic methods.」
The Group continues to pursue its vision of world-leading analysis technology, biomarker discovery and innovative diagnostic methods. - FY2017First statedAnnual report
「The Group's vision is to become a biotechnology venture that establishes the world's leading metabolome analysis technology and the definitive approach to biomarker discovery, and creates innovative diagnostic methods.」
The vision explicitly targets biomarker discovery and the creation of innovative diagnostic methods based on metabolome analysis technology.